In 1990, the United States Food and Drug Administration (FDA) approved Adagen (pegademase bovine), the world’s first PEGylated drug, for the treatment of severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase. The gene discussed is ADA; the disease is severe combined immunodeficiency.